aICAP at Columbia University, Mailman School of Public Health, Columbia University, New York, NY;
bDepartment of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY;
cResearch Program, Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC;
dHIV and Sexual Health Clinic, Chelsea and Westminster Hospital NHS Foundation Trust and LSHTM London, London, United Kingdom;
eDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, MA;
fDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA;
gBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana;
hRadboud University Medical Center, and HIV Institute, Nijmegen, the Netherlands;
iDivision of Antiviral Products, US Food and Drug Administration (FDA), Silver Spring, MD;
jHIV i-Base, London, United Kingdom;
kDepartment of Pediatrics, Boston University School of Medicine, Boston, MA;
lDivision of Prevention Care and Treatment, Office of HIV/AIDS, United States Agency for International Development (USAID), Washington, DC;
mGlobal HIV, Hepatitis and STIs Programme, World Health Organization, Geneva, Switzerland;
nDepartment of Pharmacy, Research Institute, University of Liverpool, United Kingdom; and
oEzintsha, Wits Reproductive Health Sciences, University of Witwatersrand, South Africa.
Correspondence to: Martina Penazzato, MD, DTMH, MSc, PhD, Global HIV, Hepatitis and STIs Programme, WHO, Avenue Appia, 20, CH-1202, Geneva, Switzerland (e-mail: [email protected]).
This work was developed with the generous contribution of Unitaid. This article was also made possible by the support of the American people through the United States Agency for International Development (USAID) under the US President's Emergency Plan for AIDS Relief (PEPFAR).
E.J.A. and L.M.M. participated in ViiV Dolutegravir Neural Tube Defect Advisory Board (no honorarium); A.P. has been an advisor to Merck Inc, Gilead Sciences, ViiV, and Janssen; S.K. has received research support from Janssen, Merck, Gilead, and ViiV and provided advice to Merck and ViiV; W.D.F.V. has received drug donations from ViiV and Gilead and participated in the Dolutegravir Neural Tube Defect Advisory Board and received honoraria for talks and board membership for Gilead, Viiv, Mylan, Merk, Adcock-Ingram, Aspen, Abbott, Roche, and J&J; and M.M. has received research support from Merck, Gilead, and ViiV. The other authors have no funding or conflicts of interest to disclose.
E.J.A., L.M.M., A.C., and M.P. developed the first draft after the PADO4 meeting. All authors contributed to drafts and revisions of this article.
The contents in this article are those of the authors and do not necessarily reflect the view of the US President's Emergency Plan for AIDS Relief, the U.S. Agency for International Development, or the US Government.
